International regulatory agencies may differ in their explicit or implicit requirements for Investigational New Drug (IND)-enabling drug development programs. This requires a significant amount of planning to ensure both the short- and long-term needs of global studies are met for the preclinical safety assessment of new therapeutics.Learn more by watching our webinar.